Novavax, Inc. Announces First Quarter 2026 Financial Results and Operational Highlights

Key Points for Investors

• Total Revenue: \$140 million for Q1 2026.
• Net Loss: \$(9.5) million for Q1 2026, compared to a net income of \$518.6 million for Q1 2025.
• R&D and SG&A Expenses: Combined non-GAAP R&D and SG&A expenses guidance for full year 2026 is \$310–\$340 million, after reimbursements.
• Cash Position: \$228.4 million in cash and cash equivalents as of March 31, 2026.
• Marketable Securities: \$562.0 million as of March 31, 2026.
• Working Capital: \$508.4 million as of March 31, 2026.
• Convertible Notes Payable: \$291 million as of March 31, 2026.
• Shareholder Equity: Total stockholders’ deficit of \$(144.8) million as of March 31, 2026, compared to \$(127.8) million at December 31, 2025.
• Full Year 2026 Revenue Framework: Adjusted total revenue guidance is \$230–\$270 million. This excludes Sanofi-related revenues (supply sales, royalties, milestones).

Detailed Financial Review

Income Statement Highlights

• Total Revenue: \$140 million in Q1 2026, a significant decrease compared to \$665.5 million in Q1 2025.
• Research & Development Expenses: \$95.5 million in Q1 2026, up from \$88.9 million in Q1 2025.
• Selling, General & Administrative Expenses: \$28.8 million in Q1 2026, down from \$48.1 million in Q1 2025.
• Combined R&D and SG&A Expenses: \$124.3 million in Q1 2026, down from \$137.0 million in Q1 2025. After R&D reimbursement (\$27.7 million in Q1 2026, \$11.3 million in Q1 2025), non-GAAP combined expenses are lower.
• Operating Loss: \$(15.4) million in Q1 2026, compared to operating income of \$515.5 million in Q1 2025.
• Interest Expense: \$(4.9) million in Q1 2026, compared to \$(5.7) million in Q1 2025.
• Other Income, Net: \$11.8 million in Q1 2026, compared to \$10.1 million in Q1 2025.
• Net Loss: \$(9.5) million in Q1 2026, versus net income of \$518.6 million in Q1 2025.
• Earnings per Share: Basic and diluted net loss per share was \$(0.06) in Q1 2026, compared to earnings per share of \$3.22 (basic) and \$2.93 (diluted) in Q1 2025.

Balance Sheet Highlights

• Cash & Cash Equivalents: \$228.4 million as of March 31, 2026, down from \$240.6 million at December 31, 2025.
• Marketable Securities: \$562.0 million as of March 31, 2026, up from \$494.5 million at December 31, 2025.
• Total Restricted Cash: \$4.6 million as of March 31, 2026.
• Working Capital: \$508.4 million as of March 31, 2026, compared to \$518.3 million at December 31, 2025.
• Total Assets: \$1.043 billion as of March 31, 2026, down from \$1.177 billion at December 31, 2025.
• Convertible Notes Payable: \$291.0 million as of March 31, 2026, up from \$244.2 million at December 31, 2025.
• Total Stockholders’ Deficit: \$(144.8) million as of March 31, 2026, a further decline from \$(127.8) million at December 31, 2025.

Guidance and Forward-looking Information

• 2026 Non-GAAP Combined R&D and SG&A Expenses: Expected to be \$310–\$340 million (after R&D reimbursements of \$70–\$80 million).
• 2026 Adjusted Total Revenue: Projected at \$230–\$270 million. This does not include potential revenue from Sanofi supply sales, royalties, or milestones, which could represent upside if realized.
• Potential Upside: The company specifically notes that revenues related to Sanofi (supply sales, royalties, milestones) are excluded from its full-year guidance due to dependence on Sanofi’s sales forecasts and timing, which are not currently available. Positive developments in this area could be material and are not reflected in the forecast.

Shareholder Considerations and Price-sensitive Information

• Significant Revenue Decline: There is a dramatic year-over-year drop in total revenue (\$140 million in Q1 2026 vs. \$665.5 million in Q1 2025), primarily due to the absence of one-off or large prior period sales (possibly COVID-19 vaccine contracts). This sharp decrease is likely to be price sensitive as it reflects changes in demand, product portfolio, or competitive environment.
• Net Income Swings to Loss: The company moved from net income of \$518.6 million in Q1 2025 to a net loss of \$(9.5) million in Q1 2026. This is a major reversal and will be closely watched by shareholders.
• Cash Position Remains Solid, but Stockholder Deficit Widens: While Novavax maintains a strong cash and marketable securities position (\$790 million combined), the company continues to operate at a loss and has a growing stockholder deficit. This is a critical risk factor for investors concerned about long-term sustainability and future capital needs.
• Convertible Debt Increases: Novavax’s convertible notes payable increased by nearly \$47 million in the quarter, adding to its leverage.
• Uncertain Sanofi Upside: No Sanofi-related revenues are included in guidance. If Sanofi’s sales or milestones materialize, it could drive significant upside and represent a positive catalyst for the share price. Conversely, a lack of realization could weigh on sentiment.
• Forward-Looking Risks: The company highlights risks related to partner sales, regulatory outcomes, product pipeline progress, and overall demand for COVID-19 and influenza vaccines. Key uncertainties remain around the seasonal nature of the market and potential new partnerships.

Summary Table – Q1 2026 vs. Q1 2025 (\$ in millions, except per share)

Conclusion

Novavax’s Q1 2026 results reflect a pivotal transition period as the company faces a dramatic revenue drop and swings to a net loss, while maintaining a solid cash position. The company’s 2026 guidance is conservative, notably excluding potential upside from Sanofi-related revenues, which remain a major wildcard for investors. Shareholders should be aware of the significant risks and possible catalysts involving product demand, regulatory events, and partner performance.

Any significant developments regarding Sanofi revenues, new product launches, or regulatory approvals may have a material impact on Novavax’s share price in the coming quarters.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. The information summarized herein is based on the company’s public filings and may be subject to change. Forward-looking statements are subject to risks and uncertainties, which may cause actual results to differ materially from those anticipated.

View NOVAVAX INC Historical chart here